- $60.65m
- $57.62m
- $17.78m
- 31
- 20
- 48
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.97 | ||
| Price to Tang. Book | 7.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -74.7% | ||
| Return on Equity | -40.03% | ||
| Operating Margin | -32.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.43 | 2.53 | 5.88 | 12.23 | 17.78 | 16 | 20.4 | 57.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioLargo, Inc. is a cleantech and life sciences innovator and engineering services solution provider. The Company’s core products address polyfluoroalkyl substances (PFAS) contamination, achieve advanced water and wastewater treatment, control odor and VOCs. The Company operates in distinct business segments, including ONM Environmental, which manufactures and sells its odor and VOC control products and services, including its flagship product, CupriDyne Clean; BLEST, which provides professional engineering services; Clyra Medical, which develops and sells medical products based on its technology; BETI, which develops its battery technology; BEST, which sells equipment based on its technology; BioLargo Canada, located in Edmonton, Alberta, Canada, has its primary research and development activities; and corporate operations, which support the operating segments with legal, accounting, human resources, and other services.
Directors
- Dennis Calvert CHM (58)
- Charles Dargan CFO (65)
- Kenneth Code CSO (74)
- Joseph Provenzano VOP (52)
- Dennis Marshall IND (78)
- Kent Roberts IND (61)
- John Runyan IND (82)
- Jack Strommen IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 19th, 1991
- Public Since
- December 12th, 1991
- No. of Shareholders
- 530
- No. of Employees
- 40
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 304,850,985
- Address
- 14921 Chestnut St., WESTMINSTER, 92683
- Web
- https://www.biolargo.com/
- Phone
- +1 9496439540
- Auditors
- Haskell & White LLP
Upcoming Events for BLGO
Q3 2025 BioLargo Inc Earnings Release
Similar to BLGO
Advanced Container Technologies
Pink Sheets on Nasdaq
Alkane
Pink Sheets on Nasdaq
Angstrom Technologies
Pink Sheets on Nasdaq
Asia Carbon Industries
Pink Sheets on Nasdaq
BioNitrogen Holdings
Pink Sheets on Nasdaq
FAQ
What is the BioLargo share price?
As of Today at 19:35 UTC, shares in BioLargo are trading at $0.20. This share price information is delayed by 15 minutes.
How has the BioLargo share price performed this year?
Shares in BioLargo last closed at $0.20 and the price had moved by -22.97% over the past 365 days. In terms of relative price strength the BioLargo share price has underperformed the S&P500 Index by -32.06% over the past year.
What are the analyst and broker recommendations for BioLargo?
The overall consensus recommendation for BioLargo is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioLargo dividend yield?
BioLargo does not currently pay a dividend.
Does BioLargo pay a dividend?
BioLargo does not currently pay a dividend.
When does BioLargo next pay dividends?
BioLargo does not currently pay a dividend.
How do I buy BioLargo shares?
To buy shares in BioLargo you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioLargo?
As of the previous close price of $0.20, shares in BioLargo had a market capitalisation of $60.65m.
Where are BioLargo shares listed?
Here are the trading details for BioLargo:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BLGO
What kind of share is BioLargo?
Based on an overall assessment of its quality, value and momentum BioLargo is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioLargo share price forecast for 2025?
The analyst consensus target price for shares in BioLargo is $0.35. That is 75.91% above the last closing price of $0.20.
Analysts covering BioLargo currently have a consensus Earnings Per Share (EPS) forecast of -$0.02 for the next financial year.
Find out moreWhat is the trend in the BioLargo share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioLargo. Over the past six months, its share price has underperformed the S&P500 Index by -26.17%.
As of the last closing price of $0.20, shares in BioLargo were trading -14.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioLargo PE Ratio?
The BioLargo PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioLargo?
BioLargo's management team is headed by:
- Dennis Calvert - CHM
- Charles Dargan - CFO
- Kenneth Code - CSO
- Joseph Provenzano - VOP
- Dennis Marshall - IND
- Kent Roberts - IND
- John Runyan - IND
- Jack Strommen - IND